General information

Announcements(0)

Program

Sessions

Search presentations

Timetable

Wed. Dec 3, 2025

Thu. Dec 4, 2025

Fri. Dec 5, 2025

web_header_en.png

web_icon.png

Profile management

Announcements

Bookmark

Download PDF for print

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

Please enter the password printed on your name card.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Single-cell-based evidence for GLS1 inhibitor as a bona fide senolytic agent in vivo

Where is the boundary between health and disease? In an organism composed of countless cells, how do individual cells regenerate within organs, and how do they coordinate with other cells to sustain function? What exactly is disease? What defines it?Advancements in cutting-edge technologies—such as single-cell analysis, spatial omics, digital AI, imaging, genome editing, and modeling—have dramatically transformed life science research in recent years. By integrating these state-of-the-art approaches, we are now beginning to uncover the boundary between health and disease, offering new possibilities for controlling and treating diseases. At this symposium, leading researchers at the forefront of these technologies will come together to explore how we can manipulate the balance between health and disease. Join us as we discuss the future direction of life science research.

【J】Single-cell Regulome Linking Health and Disease

The 48th Annual Meeting of the Molecular Biology Society of Japan

Presentation Information

[1AS-17-02]Single-cell-based evidence for GLS1 inhibitor as a bona fide senolytic agent in vivo

Comment